Evidence map

ArticleFrontiers in oncology2022

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the

Paola Verachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

18 papers cite it

2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 35392239